Literature DB >> 19756366

The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Avner Thaler1, Elissa Ash, Ziv Gan-Or, Avi Orr-Urtreger, Nir Giladi.   

Abstract

Mutations in the leucine rich repeat kinase 2 gene (LRRK2) are recognized as the most common cause of genetic Parkinsonism to date. The G2019S mutation has been implicated as an important determinant of Parkinson's disease (PD) in both Ashkenazi Jewish and North African Arab populations with carrier frequency of 29.7% among familial and 6% in sporadic Ashkenazi Jewish PD cases. PD patients with the G2019S mutation display similar clinical characteristics to patients with sporadic PD. While the function of the LRRK2 protein has yet to be fully determined, its distribution coincides with brain areas most affected by PD. The G2019S mutation is believed to be responsible for up-regulation of LRRK2 kinase activity, which may ultimately play a role in neuronal loss. The utility of LRRK2 G2019S screening in family members of Ashkenazi PD patients is discussed. LRRK2 G2019S mutation carriers without PD may be an ideal population for the study of possible neuroprotective strategies as they become available, and for furthering the understanding of the pathogenesis and long-term clinical outcomes of the disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756366     DOI: 10.1007/s00702-009-0303-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  106 in total

1.  Genetics of Parkinson's disease: LRRK2 on the rise.

Authors:  Alexis Brice
Journal:  Brain       Date:  2005-12       Impact factor: 13.501

2.  LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP.

Authors:  Cleanthe Spanaki; Helen Latsoudis; Andreas Plaitakis
Journal:  Neurology       Date:  2006-10-24       Impact factor: 9.910

3.  Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?

Authors:  S Lesage; S Belarbi; A Troiano; C Condroyer; N Hecham; P Pollak; E Lohman; T Benhassine; F Ysmail-Dahlouk; A Dürr; M Tazir; A Brice
Journal:  Neurology       Date:  2008-11-04       Impact factor: 9.910

4.  Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients.

Authors:  Sohan Punia; Madhuri Behari; Shyla T Govindappa; Pazhayannur V Swaminath; Sachi Jayaram; Vinay Goyal; Uday B Muthane; R C Juyal; B K Thelma
Journal:  Neurosci Lett       Date:  2006-10-18       Impact factor: 3.046

5.  Age estimate of the N370S mutation causing Gaucher disease in Ashkenazi Jews and European populations: A reappraisal of haplotype data.

Authors:  R Colombo
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

6.  Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.

Authors:  C H Williams-Gray; A Goris; T Foltynie; J Brown; M Maranian; A Walton; D A S Compston; S J Sawcer; R A Barker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05       Impact factor: 10.154

7.  Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase.

Authors:  Junpeng Deng; Patrick A Lewis; Elisa Greggio; Eli Sluch; Alexandra Beilina; Mark R Cookson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

8.  Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.

Authors:  L Gao; P Gómez-Garre; F J Díaz-Corrales; F Carrillo; M Carballo; A Palomino; J Díaz-Martín; R Mejías; P J Vime; J López-Barneo; P Mir
Journal:  Eur J Neurol       Date:  2009-03-31       Impact factor: 6.089

9.  LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease.

Authors:  Biswanath Patra; Azemat J Parsian; Brad A Racette; Jing Hua Zhao; Joel S Perlmutter; Abbas Parsian
Journal:  Parkinsonism Relat Disord       Date:  2008-08-26       Impact factor: 4.891

Review 10.  Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Authors:  Elisa Greggio; Mark R Cookson
Journal:  ASN Neuro       Date:  2009-04-14       Impact factor: 4.146

View more
  17 in total

1.  Clinical expression of LRRK2 G2019S mutations in the elderly.

Authors:  Marta San Luciano; Richard B Lipton; Cuiling Wang; Mindy Katz; Molly E Zimmerman; Amy E Sanders; Laurie J Ozelius; Susan B Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

2.  Association between Parkinson's disease and G2019S and R1441C mutations of the LRRK2 gene.

Authors:  Xiao-Xia Li; Qin Liao; Huan Xia; Xin-Ling Yang
Journal:  Exp Ther Med       Date:  2015-07-27       Impact factor: 2.447

3.  A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation Analysis.

Authors:  Nir Giladi; Anat Mirelman; Avner Thaler; Avi Orr-Urtreger
Journal:  Front Neurol       Date:  2016-05-10       Impact factor: 4.003

4.  Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers.

Authors:  Yael Jacob; Keren Rosenberg-Katz; Tanya Gurevich; Rick C Helmich; Bastiaan R Bloem; Avi Orr-Urtreger; Nir Giladi; Anat Mirelman; Talma Hendler; Avner Thaler
Journal:  Hum Brain Mapp       Date:  2019-02-21       Impact factor: 5.038

Review 5.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

6.  Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.

Authors:  Avner Thaler; Anat Mirelman; Tanya Gurevich; Ely Simon; Avi Orr-Urtreger; Karen Marder; Susan Bressman; Nir Giladi
Journal:  Neurology       Date:  2012-08-22       Impact factor: 9.910

7.  Frequency of the LRRK2 G2019S mutation in South African patients with Parkinson's disease.

Authors:  Nicola du Toit; Riaan van Coller; David G Anderson; Jonathan Carr; Soraya Bardien
Journal:  Neurogenetics       Date:  2019-09-06       Impact factor: 2.660

8.  Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor.

Authors:  John M Hatcher; Jinwei Zhang; Hwan Geun Choi; Genta Ito; Dario R Alessi; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2015-04-07       Impact factor: 4.345

9.  A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci.

Authors:  Eimear E Kenny; Itsik Pe'er; Amir Karban; Laurie Ozelius; Adele A Mitchell; Sok Meng Ng; Monica Erazo; Harry Ostrer; Clara Abraham; Maria T Abreu; Gil Atzmon; Nir Barzilai; Steven R Brant; Susan Bressman; Edward R Burns; Yehuda Chowers; Lorraine N Clark; Ariel Darvasi; Dana Doheny; Richard H Duerr; Rami Eliakim; Nir Giladi; Peter K Gregersen; Hakon Hakonarson; Michelle R Jones; Karen Marder; Dermot P B McGovern; Jennifer Mulle; Avi Orr-Urtreger; Deborah D Proctor; Ann Pulver; Jerome I Rotter; Mark S Silverberg; Thomas Ullman; Stephen T Warren; Matti Waterman; Wei Zhang; Aviv Bergman; Lloyd Mayer; Seymour Katz; Robert J Desnick; Judy H Cho; Inga Peter
Journal:  PLoS Genet       Date:  2012-03-08       Impact factor: 5.917

10.  Implications for health and disease in the genetic signature of the Ashkenazi Jewish population.

Authors:  Saurav Guha; Jeffrey A Rosenfeld; Anil K Malhotra; Annette T Lee; Peter K Gregersen; John M Kane; Itsik Pe'er; Ariel Darvasi; Todd Lencz
Journal:  Genome Biol       Date:  2012-01-25       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.